Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the call transcript. Current debt levels are flat, but interest costs have increased due to higher working capital utilization. Capex plans for FY '26 and '27 are around INR 200 crores each year, indicating planned investments are likely to be funded internally or from existing resources. No reference to raising equity or additional debt to fund operations or expansions. Focus appears to be on operational optimization and organic growth rather than new fundraising activities.

Any current/future capex/capital investment/strategic investment?

Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27. Investment is focused on capacity, talent, and technology to support scale readiness and enhance competitive edge. A new high-potency chemistry laboratory (mini pilot plant) is being commissioned by Q3 FY '26 to enable participation in high-potency anticancer drug projects and early clinical trial material production. Continued investments are being made in R&D, allocating 4-5% of revenue toward innovation. Specialty Chemicals portfolio expansion utilizes existing Crop Protection assets to improve capaci

Future growth expectations in sales/revenue/volumes?

Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects. Crop Protection business anticipated to remain flattish in FY '26 with growth resuming from FY '27 onwards as market stabilizes and new product launches ramp up. Animal Health segment showing strong momentum with a healthy pipeline and increasing regulatory oversight, signaling future growth potential. New high-potency chemistry laboratory coming online by Q3 FY '26, expected to increase participation in high-value RFQs and add to growth. CDMO segm

Future growth expectations in earnings/operating earnings/profits/EPS?

Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12). CDMO segment growth driven by promising early-stage projects and increased inquiries, especially in high-potent chemistry (Pages 4, 7, 12, 14). Crop Protection business to remain flat/muted in FY '26, with growth resuming from FY '27 onwards (Pages 4, 7, 11). ROE and ROCE may slightly decline or remain flat in FY '26 due to higher depreciation related to Crop business capex (Page 11). Operating leverage and cost optimization expected to sustain margin improvements in Pharma

Current/ Expected Orderbook/ Pending Orders?

The Crop Protection CDMO division is managing a robust pipeline of 8 active projects with existing and new strategic customers. The Animal Health segment has received validation for 8 products and is working with multiple innovators. The Pharma business has around 12 to 15 products in advanced stages of development and commercialization, up from 6 to 9 the previous year (more than 50% increase). The new high-potent chemistry lab expected to be operational by Q3 FY '26 will increase participation in RFQs, potentially boosting project inflow by 30-40% or more. Continued strong inflow of RFPs in

IN US

Sale is live|00:00:00left today

Hikal LtdQ1 FY25Pharmaceuticals & Biotechnology

Hikal Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Pharma business expected to grow at approximately 12% to 15% revenue growth in FY '26, driven by increased CDMO inquiries and development projects.
→Crop Protection business anticipated to remain flattish in FY '26 with growth resuming from FY '27 onwards as market stabilizes and new product launches ramp up.
→Animal Health segment showing strong momentum with a healthy pipeline and increasing regulatory oversight, signaling future growth potential.
→New high-potency chemistry laboratory coming online by Q3 FY '26, expected to increase participation in high-value RFQs and add to growth.
→CDMO segment managing a robust pipeline of 12 to 15 new opportunities, supporting long-term growth and diversification.
→Specialty Chemicals portfolio launching new products from second half of FY '26, improving capacity utilization and operational leverage.
→Overall, strong growth outlook for FY '27 and beyond driven by innovation, expanded geographic footprint, and enhanced technology capabilities.

Margin guidance

Category 3

→Pharma business expected to grow 12% to 15% revenue in FY '26 with corresponding EBIT margin improvement (Page 4, 7, 12).
→CDMO segment growth driven by promising early-stage projects and increased inquiries, especially in high-potent chemistry (Pages 4, 7, 12, 14).
→Crop Protection business to remain flat/muted in FY '26, with growth resuming from FY '27 onwards (Pages 4, 7, 11).
→ROE and ROCE may slightly decline or remain flat in FY '26 due to higher depreciation related to Crop business capex (Page 11).
→Operating leverage and cost optimization expected to sustain margin improvements in Pharma; Crop Protection margins to improve to historical levels by FY '27 (Page 4, 11).
→Capex of approx INR 200 crores planned for FY '26 and FY '27 to support growth, especially in new capabilities (Page 10).
→Overall, earnings/profits expected to improve driven by Pharma and CDMO growth while Crop Protection stabilizes.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any new fundraising through debt or equity in the call transcript.
→Current debt levels are flat, but interest costs have increased due to higher working capital utilization.
→Capex plans for FY '26 and '27 are around INR 200 crores each year, indicating planned investments are likely to be funded internally or from existing resources.
→No reference to raising equity or additional debt to fund operations or expansions.
→Focus appears to be on operational optimization and organic growth rather than new fundraising activities.

Order book

Yes

→The Crop Protection CDMO division is managing a robust pipeline of 8 active projects with existing and new strategic customers.
→The Animal Health segment has received validation for 8 products and is working with multiple innovators.
→The Pharma business has around 12 to 15 products in advanced stages of development and commercialization, up from 6 to 9 the previous year (more than 50% increase).
→The new high-potent chemistry lab expected to be operational by Q3 FY '26 will increase participation in RFQs, potentially boosting project inflow by 30-40% or more.
→Continued strong inflow of RFPs in both Pharma and Crop Protection businesses, with increasing trust from global innovators.
→Overall, the orderbook and pending projects demonstrate healthy growth and diversified opportunities across all business verticals.

Capex plans

Yes

→Hikal Limited plans capex of approximately INR 200 crores each year for FY '26 and FY '27.
→Investment is focused on capacity, talent, and technology to support scale readiness and enhance competitive edge.
→A new high-potency chemistry laboratory (mini pilot plant) is being commissioned by Q3 FY '26 to enable participation in high-potency anticancer drug projects and early clinical trial material production.
→Continued investments are being made in R&D, allocating 4-5% of revenue toward innovation.
→Specialty Chemicals portfolio expansion utilizes existing Crop Protection assets to improve capacity utilization.
→The company is actively engaging in several advanced CDMO projects expected to commercialize from FY '27 onwards.

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio